Uncategorized
Chairman highlights 2016 industry highlights at OIS
CHICAGO — The past year has seen a number of important approvals and promising study progress in both biotechnology and ophthalmic devices, Emmett T. Cunningham Jr., MD, PhD, MPH, told the more than 900 attendees at the Ophthalmology Innovation Summit in his “Chairman’s 2016 Year in Review.”Leading approvals this yearincludeShire’s Xiidra (lifitegrast), which isthe firstapproval of adry eyetreatmentin nearly 15 years, according to Cunningham.In addition, cross-linking from Avedro, which has been availableinternationallyfor some time,wasapproved for use in the United States.